Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 7/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.44 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427271 | 0.71 | LIPE (0.58) | SMN1; SMN2MGLLKMT2AALDH1A1LMNA | |
| SCHEMBL19468081 | 0.71 | NR1H2 (0.35) | SMN1; SMN2NR1H2NR1H3ALDH1A1 | |
| SCHEMBL427439 | 0.70 | ALDH1A1 (0.44) | SMN1; SMN2KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL424517 | 0.69 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL424347 | 0.69 | LIPE (0.56) | SMN1; SMN2MGLLKMT2AKDM4EALDH1A1 | |
| SCHEMBL425530 | 0.69 | ELANE (0.47) | SMN1; SMN2KMT2AKDM4EALDH1A1 | |
| SCHEMBL425384 | 0.68 | LMNA (0.52) | SMN1; SMN2MGLLKMT2AKDM4EALDH1A1 | |
| SCHEMBL2182855 | 0.68 | MGLL (0.85) | MGLLTRPV1DAGLATRPA1 | |
| SCHEMBL18780849 | 0.66 | LMNA (0.52) | KMT2AALDH1A1LMNA | |
| SCHEMBL426663 | 0.66 | SCN4A (0.48) | SMN1; SMN2KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| WO-2010074588-A2 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | SMN1; SMN2 2818/4885MGLL 11/4885TRPV1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.